Stocks and Investing
Stocks and Investing
Fri, December 16, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tiago Fauth Initiated (VRDN) at Buy and Held Target at $51 on, Dec 16th, 2022
Tiago Fauth of Credit Suisse, Initiated "Viridian Therapeutics, Inc." (VRDN) at Buy and Held Target at $51 on, Dec 16th, 2022.
Tiago has made no other calls on VRDN in the last 4 months.
There are 3 other peers that have a rating on VRDN. Out of the 3 peers that are also analyzing VRDN, 0 agree with Tiago's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Tiago
- Douglas Tsao of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $35 on, Thursday, December 1st, 2022
- Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $46 on, Tuesday, November 15th, 2022
- Michael Higgins of "Ladenburg Thalmann" Maintained at Strong Buy with Increased Target to $40 on, Tuesday, August 16th, 2022
Contributing Sources